SCHEMBL6287560

SCHEMBL6287560

C/C(=N/NC(=N)N)c1cn(S(=O)(=O)c2cccc3ccccc23)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.46
DRD2 P14416 2/20 0.45
HTR2A P28223 1/20 0.45
HTR7 P34969 1/20 0.45
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
F2 P00734 3/20 0.42
PRSS1 P07477 3/20 0.42
PRSS2 P07478 3/20 0.42
PRSS3 P35030 3/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
FABP4 P15090 2/20 0.41
PLK1 P53350 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287562 1.00 HTR6 (0.46) HTR6DRD2HTR2AHTR7LMNA
SCHEMBL6286325 0.88 HTR6 (0.48) HTR6LMNASMN1; SMN2FABP4PLK1
SCHEMBL6286328 0.88 HTR6 (0.48) HTR6LMNASMN1; SMN2FABP4PLK1
SCHEMBL6286239 0.88 F2 (0.46) HTR6LMNASMN1; SMN2F2PRSS1
SCHEMBL6286243 0.88 F2 (0.46) HTR6LMNASMN1; SMN2F2PRSS1
SCHEMBL6286906 0.86 LMNA (0.60) HTR6LMNASMN1; SMN2CA2CA9
SCHEMBL6286909 0.86 LMNA (0.60) HTR6LMNASMN1; SMN2CA2CA9
SCHEMBL6286249 0.85 CA2 (0.44) HTR6HTR2ALMNASMN1; SMN2F2
SCHEMBL6286245 0.85 CA2 (0.44) HTR6HTR2ALMNASMN1; SMN2F2
SCHEMBL6285290 0.85 TNFSF11 (0.46) HTR6DRD2HTR2AHTR7LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885DRD2 190/4885HTR2A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.